Innventure Shifts to ATM Program, Discontinues SEPA Financing…

Event summary

Innventure established an at-the-market (ATM) equity program with a $60M offering size, replacing its SEPA agreement with YA II PN, Ltd.
The ATM program allows flexible equity sales over an extended period, controlled by an independent board committee.
CEO Dr. Bill Grieco emphasized disciplined capital management and cost reduction as strategic priorities.
The shift to ATM follows Innventure's eligibility for a Form S-3 shelf registration statement.
The company aims to use the ATM to support Accelsius' development and operational costs.

The big picture

Innventure's move to an ATM program reflects a broader trend among biotech firms seeking flexible financing options amid volatile capital markets. The shift from SEPA to ATM suggests a strategic pivot toward greater financial autonomy and disciplined capital allocation, aligning with industry practices where companies prioritize operational control over pre-committed funding structures. The $60M offering size indicates a significant scaling of Innventure's financing capacity, positioning it to support Accelsius' growth while managing shareholder dilution.

What we're watching

Capital Discipline: How Innventure balances equity dilution with operational funding needs under the ATM program.
Accelsius Milestones: The pace at which Accelsius achieves commercialization goals with the new financing structure.
Market Conditions: Whether Innventure's equity sales timing aligns with favorable market conditions to minimize dilution.